An EU-wide approach to HTA: an irrelevant development or an opportunity not to be missed?

P. Kanavos; A. Angelis; M.F. Drummond

doi:10.1007/s10198-019-01037-2

An EU-wide approach to HTA: an irrelevant development or an opportunity not to be missed?

P. Kanavos, A. Angelis, M.F. Drummond

Centre for Health Economics

Research output: Contribution to journal › Editorial › peer-review

Abstract

An EU-wide cooperation on HTA has been proposed recently by the European Commission, focusing on relative effectiveness assessment (REA) for pharmaceuticals and medical devices. While a good step in the right direction, this collaborative HTA framework needs to be more explicit and pragmatic about clinical value definition, what constitutes quality of evidence, how is real world evidence handled, whether the same assessment requirements will apply for medical devices as they do for pharmaceuticals, and how to safeguard consistency in REA interpretation. If demand- rather than supply-driven, this initiative can deliver wider benefits: Europe can improve its power in global drug design and development, while Member States will have at their disposal more resources to assess performance of interventions in their healthcare systems.

Original language	English
Pages (from-to)	329-332
Number of pages	4
Journal	European Journal of Health Economics
Volume	20
Issue number	3
Early online date	14 Mar 2019
DOIs	https://doi.org/10.1007/s10198-019-01037-2
Publication status	E-pub ahead of print - 14 Mar 2019

Bibliographical note

Access to Document

10.1007/s10198-019-01037-2

PK AA MFD EU-wideApproachHTA EJHE epub 140319
© The Author(s) 2019
Final published version, 387 KBLicence: CC BY

Cite this

@article{e5e6de4052b445be99ea609e57b22f24,

title = "An EU-wide approach to HTA: an irrelevant development or an opportunity not to be missed?",

abstract = "An EU-wide cooperation on HTA has been proposed recently by the European Commission, focusing on relative effectiveness assessment (REA) for pharmaceuticals and medical devices. While a good step in the right direction, this collaborative HTA framework needs to be more explicit and pragmatic about clinical value definition, what constitutes quality of evidence, how is real world evidence handled, whether the same assessment requirements will apply for medical devices as they do for pharmaceuticals, and how to safeguard consistency in REA interpretation. If demand- rather than supply-driven, this initiative can deliver wider benefits: Europe can improve its power in global drug design and development, while Member States will have at their disposal more resources to assess performance of interventions in their healthcare systems.",

author = "P. Kanavos and A. Angelis and M.F. Drummond",

note = "{\textcopyright} The Author(s) 2019",

year = "2019",

month = mar,

day = "14",

doi = "10.1007/s10198-019-01037-2",

language = "English",

volume = "20",

pages = "329--332",

journal = "European Journal of Health Economics",

issn = "1618-7598",

publisher = "Springer",

number = "3",

}

TY - JOUR

T1 - An EU-wide approach to HTA

T2 - an irrelevant development or an opportunity not to be missed?

AU - Kanavos, P.

AU - Angelis, A.

AU - Drummond, M.F.

PY - 2019/3/14

Y1 - 2019/3/14

N2 - An EU-wide cooperation on HTA has been proposed recently by the European Commission, focusing on relative effectiveness assessment (REA) for pharmaceuticals and medical devices. While a good step in the right direction, this collaborative HTA framework needs to be more explicit and pragmatic about clinical value definition, what constitutes quality of evidence, how is real world evidence handled, whether the same assessment requirements will apply for medical devices as they do for pharmaceuticals, and how to safeguard consistency in REA interpretation. If demand- rather than supply-driven, this initiative can deliver wider benefits: Europe can improve its power in global drug design and development, while Member States will have at their disposal more resources to assess performance of interventions in their healthcare systems.

AB - An EU-wide cooperation on HTA has been proposed recently by the European Commission, focusing on relative effectiveness assessment (REA) for pharmaceuticals and medical devices. While a good step in the right direction, this collaborative HTA framework needs to be more explicit and pragmatic about clinical value definition, what constitutes quality of evidence, how is real world evidence handled, whether the same assessment requirements will apply for medical devices as they do for pharmaceuticals, and how to safeguard consistency in REA interpretation. If demand- rather than supply-driven, this initiative can deliver wider benefits: Europe can improve its power in global drug design and development, while Member States will have at their disposal more resources to assess performance of interventions in their healthcare systems.

UR - http://www.scopus.com/inward/record.url?scp=85063008186&partnerID=8YFLogxK

U2 - 10.1007/s10198-019-01037-2

DO - 10.1007/s10198-019-01037-2

M3 - Editorial

SN - 1618-7598

VL - 20

SP - 329

EP - 332

JO - European Journal of Health Economics

JF - European Journal of Health Economics

IS - 3

ER -

An EU-wide approach to HTA: an irrelevant development or an opportunity not to be missed?

Abstract

Bibliographical note

Access to Document

Other files and links

Cite this